Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
News|Articles|August 1, 2025
Top 5 women's health headlines you missed in July 2025
Author(s)Morgan Ebert
Fact checked by: Celeste Krewson, Assistant Editor
Take a quick look at everything you may have missed last month, including the latest FDA updates, top stories, and exclusive interviews.
Advertisement
Advertisement
July 2025 brought a wave of important updates that continue to shape the care of women across all stages of life.
Related to this article
JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.
The FDA approved the first generic of Climara Pro, a weekly estradiol/levonorgestrel patch for VMS and osteoporosis prevention in women with a uterus.
In September, the FDA accepted an extended duration sNDA for the IUD with a decision expected in Q2 2027.
Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.
Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.
Advertisement
Advertisement